EL7.AI
StocksMediumUpdated•Originally published 22 September 2026•Updated 22 September 2026•
2 min read

Roche’s Enicepatide Cuts Weight by Up to 22.7% Over 48 Weeks in Phase 2

Key Facts

1Enicepatide delivered weight loss of up to 22.7% after 48 weeks in phase 2.
2Among participants with prediabetes, 73% achieved normal glucose levels, versus 7.5% on placebo.
3The phase 2 trial involved 469 adults without type 2 diabetes.
4RHHVF closed at $443.3 within a $435.32-to-$450 range on September 21, 2026.

Roche presented detailed results from a phase 2 trial of enicepatide involving 469 adults with obesity or overweight but without type 2 diabetes. The drug produced weight loss of up to 22.7% after 48 weeks, according to the company's June 2026 presentation.

In the 24 mg group, 87% of participants lost at least 10% of their body weight and 47.8% lost at least 20%. Among those with prediabetes at baseline, 73% achieved normal glucose levels after 48 weeks, versus 7.5% on placebo.

Enicepatide is a dual GLP-1/GIP receptor agonist, targeting pathways involved in appetite and glucose regulation. Activating those pathways can reduce appetite and regulate blood sugar, explaining why investors track weight and metabolic outcomes together.

Genentech said most gastrointestinal adverse events were mild to moderate, while treatment discontinuation due to adverse events was 5.9% across enicepatide groups and 1.3% with placebo. The drug remains investigational, and the program has advanced to phase 3, including a recruiting study in adults with obesity or overweight and type 2 diabetes.

RHHVF closed at $443.3 on September 21, 2026 after trading between $435.32 and $450. The available data provide no percentage change that would support linking the trading range to the news; for investors, the drug's potential value and development risk depend on phase 3 confirmation of efficacy and safety, not the phase 2 results alone.